To date, most efforts to inhibit PIM in cancer treatment have focused on a monotherapeutic approach, generally using ATP (adenosine triphosphate)-competitive drugs that target the kinase action of the protein, preventing it from phosphorylating its downstream effectors, either through quinones or other classes of small molecule inhibitors43–45 (Table 1). Here, PIM1 is linked to cancer.